Can AZN sustain its earnings momentum into 2025?

**AstraZeneca (AZN) is poised to sustain its earnings momentum into 2025**, considering the following factors:

1. **Strong Financial Performance**: AZN's recent financials show robust growth, with a net income of $1.5 billion and a revenue of $14.89 billion in the most recent quarter. The diluted EPS grew by 54.84%, indicating efficiency and profitability.

|code|Ticker|Name|Date|Net Income YoY|Total Revenue YoY|Diluted EPS YoY|market_code|
|---|---|---|---|---|---|---|---|
|AZN|AZN.O|Astrazeneca|2024 Q1|20.84257206208426|16.545638385881055|20.689655172413794|185|
|AZN|AZN.O|Astrazeneca|2024 Q2|5.934065934065933|13.332165381920111|5.982905982905988|185|
|AZN|AZN.O|Astrazeneca|2024 Q3|3.991291727140784|18.038635572572222|3.4090909090909123|185|
|AZN|AZN.O|Astrazeneca|2024 Q4|56.41293013555787|23.84397870924817|54.83870967741935|185|

|code|Ticker|Name|Date|Total Revenue|Net Income|market_code|
|---|---|---|---|---|---|---|
|AZN|AZN.O|Astrazeneca|2024 Q1|1.2679E10|2.18E9|185|
|AZN|AZN.O|Astrazeneca|2024 Q2|1.2938E10|1.928E9|185|
|AZN|AZN.O|Astrazeneca|2024 Q3|1.3565E10|1.433E9|185|
|AZN|AZN.O|Astrazeneca|2024 Q4|1.4891E10|1.5E9|185|

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|AZN|AZN.O|Astrazeneca|2024 Q1|20.689655172413794|1.4|185|
|AZN|AZN.O|Astrazeneca|2024 Q2|5.982905982905988|1.24|185|
|AZN|AZN.O|Astrazeneca|2024 Q3|3.4090909090909123|0.91|185|
|AZN|AZN.O|Astrazeneca|2024 Q4|54.83870967741935|0.96|185|

2. **Analyst Confidence**: The consensus rating is a "Strong Buy" with an average analyst price target suggesting upside potential. Recent analyst actions, such as Morgan Stanley's "Overweight" rating and Goldman Sachs' "Conviction Buy" rating, further support this view.
3. **Growth Prospects**: AZN's 3-year CAGRs for net income, revenue, and diluted EPS are impressive, with net income and diluted EPS growing at 46.22% and 46.04%, respectively. This historical growth trajectory, coupled with current analyst optimism, suggests sustainability of earnings momentum.

4. **Market Outperformance**: AZN has outperformed the broader market in recent trading sessions, which could be a sign of investor confidence and potential for continued positive sentiment.
5. **Strategic Positioning**: AZN's focus on key therapeutic areas and its pipeline of innovative drugs, such as AZD0780, position it well for sustained growth.

In conclusion, AstraZeneca's strong financial performance, analyst confidence, growth prospects, market outperformance, and strategic positioning suggest that it is well-equipped to sustain its earnings momentum into 2025.